Pathstone Family Office’s Tvardi Therapeutics TVRD Stock Holding History

Pathstone Family Office’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3	Closed	-$1K	–	998
2020 Q1	$1K	Buy	+3	New	+$1.63K	﹤0.01%	742

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's TVRD Position: Q2 2020 in Review

Pathstone Family Office sold out of Tvardi Therapeutics (TVRD) in Q2 2020, closing a stake of 3 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in TVRD in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 145 funds tracked by Wall St. Rank hold TVRD as of Q2 2020.

Pathstone Family Office reported no remaining Tvardi Therapeutics position as of Q2 2020 after selling out during the quarter.
Pathstone Family Office sold 3 Tvardi Therapeutics shares in Q2 2020, an estimated $1K.
Pathstone Family Office first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 1 quarter.
Pathstone Family Office's Tvardi Therapeutics position peaked at $1K in Q1 2020.
145 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.